Recent events
Recent events tied to this brand in public sources.
Back to profile6 entries
2026
Aurobindo Pharma acquires Khandelwal Laboratories' non-oncology prescription business for Rs 325 crore
Aurobindo Pharma, through its wholly owned subsidiary Auro Pharma Limited, acquired the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd on a going concern, slump sale basis for a cash consideration of Rs 325 crore, effective January 1, 2026. The acquired business comprises 23 established brands across 67 SKUs and nine pipeline products in pain management and anti-infective segments, with a turnover of Rs 113.5 crore, and is supported by a field force of approximately 470 personnel and over 1,600 stockists across India.
2022
Aurobindo Pharma announces acquisition of Veritaz's domestic formulations business
Aurobindo Pharma said it had acquired Veritaz's domestic formulations business for Rs 171 crore. The text says the transaction would come into effect from April 1, 2022, and was expected to be completed by May 2022.
2021
Aurobindo Pharma announces investment for 51% stake in Cronus
Aurobindo Pharma entered into definitive agreements to subscribe to fresh equity shares in Cronus for Rs. 420 Crores, subject to closing conditions. Following the investment, Aurobindo Pharma would own 51% of Cronus's equity share capital.
2020
Astellas files patent-infringement complaint against pharmaceutical companies
Astellas Pharma Inc. and affiliated plaintiffs filed a complaint in Delaware against 21 pharmaceutical companies, alleging that their proposed generic versions of Myrbetriq would infringe the ’780 patent. The plaintiffs sought court relief; the allegations are claims in the complaint.
2020
Aurobindo collaborates with CSIR laboratories on COVID-19 vaccines
Aurobindo said it will undertake the clinical development and commercialisation of COVID-19 vaccine candidates being developed by three CSIR laboratories: CSIR-CCMB, CSIR-IMTech and IICB.
2020
Aurobindo Pharma and others sued over alleged metformin contamination concealment
MSP Recovery filed a class action in a U.S. court against Aurobindo Pharma and other drug makers, alleging concealment of information about the cancer-causing agent NDMA in metformin. The article reports that Valisure’s tests found NDMA in metformin produced by Aurobindo and Heritage, while also noting that Aurobindo passed the FDA test for NDMA presence.